Key Takeaways
- • Invidia Capital, the healthcare-focused private equity firm founded by former Goldman Sachs partner Jo Natauri, is nearing its first deal as it pursues upper-middle market buyouts in healthcare with target investments ranging from $100 million to $300 million per transaction.
- • Invidia raised $850 million for its debut fund with GCM Grosvenor serving as anchor investor, targeting a first close in Q1 2025 and planning six to eight total investments across pharma services, medtech, healthcare IT, delivery transformation, and consumer-oriented healthcare.
- • The fertility services sector is experiencing significant M&A activity, with transaction volumes doubling from historical peaks—11 deals in the most recent period versus six deals in 2015—indicating strong investor appetite for consolidation in reproductive medicine.
- • Invidia's investment thesis centers on healthcare as a defensive sector with structural tailwinds, leveraging mega-cap investing discipline applied to middle-market opportunities where long-term value creation is driven by operational improvements and cost efficiencies.
Summary
Invidia Capital Management, founded by Jo Natauri following her departure from Goldman Sachs in December 2024, is advancing toward its first deal as the healthcare-focused private equity firm executes its strategy of acquiring upper-middle market healthcare businesses. Natauri, who spent 17 years at Goldman Sachs and served as global head of private healthcare and investing before her exit, launched Invidia with a thesis centered on healthcare as a sector undergoing profound transformation with defensive characteristics and sustained demand dynamics.
The firm successfully raised $850 million for its debut fund, with GCM Grosvenor anchoring the investment, according to an October 30 regulatory filing cited by Fortune. Invidia targeted a first close in Q1 2025 and structured the fund to deploy capital across six to eight transactions, with individual deal sizes ranging from $100 million to $300 million. The firm concentrates investments across four primary healthcare subsectors: supporting R&D innovation (pharma services, contract manufacturing, CROs, CDMOs); tech-enabled services (healthcare IT, payor and provider technology); delivery transformation (pharmacy services, multi-site providers, home care); and consumer-oriented healthcare (retail healthcare, primary care, women's health).
The timing of Invidia's market entry aligns with heightened M&A activity in fertility services specifically. Transaction volumes in the fertility sector have peaked, with 11 deals recorded in the most recent measurement period—nearly double the previous peak of six deals in 2015. This consolidation trend reflects broader institutional investor interest in reproductive medicine networks. Industry players including First Fertility (backed by Sverica Capital) and INVO Fertility have completed acquisitions to expand regional footprints, with INVO acquiring Family Beginnings, an Indiana-based fertility clinic, for $750,000 in a transaction expected to close by February 27, 2026.
Natauri's investment philosophy emphasizes applying "mega-cap investing discipline and rigor to the middle market," a segment with documented outperformance history in private equity. The strategy prioritizes partnerships with high-quality operators and management teams to improve patient outcomes while driving operational cost efficiencies and long-term value creation across the healthcare ecosystem. The firm is also recruiting experienced healthcare dealmakers to strengthen its investment capacity.
The firm successfully raised $850 million for its debut fund, with GCM Grosvenor anchoring the investment, according to an October 30 regulatory filing cited by Fortune. Invidia targeted a first close in Q1 2025 and structured the fund to deploy capital across six to eight transactions, with individual deal sizes ranging from $100 million to $300 million. The firm concentrates investments across four primary healthcare subsectors: supporting R&D innovation (pharma services, contract manufacturing, CROs, CDMOs); tech-enabled services (healthcare IT, payor and provider technology); delivery transformation (pharmacy services, multi-site providers, home care); and consumer-oriented healthcare (retail healthcare, primary care, women's health).
The timing of Invidia's market entry aligns with heightened M&A activity in fertility services specifically. Transaction volumes in the fertility sector have peaked, with 11 deals recorded in the most recent measurement period—nearly double the previous peak of six deals in 2015. This consolidation trend reflects broader institutional investor interest in reproductive medicine networks. Industry players including First Fertility (backed by Sverica Capital) and INVO Fertility have completed acquisitions to expand regional footprints, with INVO acquiring Family Beginnings, an Indiana-based fertility clinic, for $750,000 in a transaction expected to close by February 27, 2026.
Natauri's investment philosophy emphasizes applying "mega-cap investing discipline and rigor to the middle market," a segment with documented outperformance history in private equity. The strategy prioritizes partnerships with high-quality operators and management teams to improve patient outcomes while driving operational cost efficiencies and long-term value creation across the healthcare ecosystem. The firm is also recruiting experienced healthcare dealmakers to strengthen its investment capacity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.